Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 779 participants.
Also called NCT02991118
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 779 participants
- Sponsor
- Registry
-
NCT02991118 -
2016-003486-26
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02991118. Randomized; triple masking; primary purpose treatment. Start 2016-11-18 (actual); primary completion 2018-08-22 (actual). Results posted on 2020-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
- Acronym
- CLEAR Wisdom
- Condition
- Hypercholesterolemia
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- bempedoic acid
- Intervention (Drug)
- placebo
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02991118- Content hash
e9cbbfa71872a43fc91b8931f121f86f800cd2aab74234fb06bca98ef6d3049c